Search

Romidepsin

Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy

Zosuquidar

Zosuquidar is a compound of antineoplastic drug candidates currently under development. It is now in "Phase 3" of clinical tests in the United States.

Pixantrone

It will compare pixantrone efficacy to that of gemcitabine. [2] … Pixantrone does not bind iron and promotes the formation of reactive oxygen species to a lesser degree than other anthracyclines.

Icatibant

Icatibant is a synthetic decapeptide with 5 nonproteinogenic amino acid antagonist targeting the B₂ receptors with a similar affinity to bradykinin. … It is resistant to bradykinin-cleaving enzyme degradation and has a potency of 2-3 times higher than earlier B₂ receptors antagonists, thus representing a new class of medication.

Rufinamide

Rufinamide is a triazole derivative and an anticonvulsant medication to treat seizure disorders like Lennox-Gastuat syndrome, a form of childhood epilepsy.

Sugammadex

Sugammadex provides a new treatment option to reverse the effects of those medications and possibly help patients recover sooner post-surgery. … Sugammadex is a selective relaxant binding agent indicated for reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide during surgery.

Tolvaptan

Tolvaptan is used to treat low blood sodium levels (hyponatremia) associated with various conditions like congestive heart failure, cirrhosis, and syndrome of inappropriate antidiuretic hormones (SIADH). FDA approved on May 19, 2009.

Alicaforsen

Vadimezan

Amelubant